Cargando…
How COVID-19 could benefit tuberculosis and HIV services in South Africa
Autores principales: | Keene, Claire, Mohr-Holland, Erika, Cassidy, Tali, Scott, Vera, Nelson, Aurelie, Furin, Jennifer, Triviño-Duran, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398675/ https://www.ncbi.nlm.nih.gov/pubmed/32758439 http://dx.doi.org/10.1016/S2213-2600(20)30311-8 |
Ejemplares similares
-
Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020) -
Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic
por: Mohr-Holland, Erika, et al.
Publicado: (2021) -
The incalculable costs of tuberculosis
por: Cox, Helen, et al.
Publicado: (2021) -
What could fair allocation of an efficacious COVID-19 vaccine look like in South Africa?
por: Moodley, Keymanthri, et al.
Publicado: (2021) -
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
por: Mohr, Erika, et al.
Publicado: (2018)